Myeloma Matters: Prevention and Management of Bispecific Antibody–Associated Adverse Events in Multiple Myeloma
IMPORTANT NOTE: This activity is not accredited for CME/CE credit.
Jointly provided by
Support for this activity has been provided through educational grants from Johnson & Johnson and Pfizer, Inc.
Release date: 7/18/2024
Expiration date: 7/18/2026
Estimated time to complete: 1 hour
Overview
This episode of Myeloma Matters features discussions of bispecific antibody therapy, a powerful form of targeted immunotherapy that has produced high response rates and helped patients—even those with multiply relapsed or refractory multiple myeloma (RRMM)—achieve deeper and more sustained responses. This podcast will also review strategies for preventing and managing the serious, potentially life-threatening, adverse events (AEs) associated with myeloma bispecific antibody therapy, which include cytokine release syndrome (CRS), neurotoxicity, and infection.
Faculty
Jesus G. Berdeja, MD—Program Chair
Director of Multiple Myeloma Research
Greco-Hainsworth Tennessee Oncology Centers for Research
Nashville, Tennessee
Nicholas G. Barkemeyer, MPAS
Physician Assistant Certified
Tennessee Oncology
Nashville, Tennessee
Ajai Chari, MD
Director of Multiple Myeloma Program
Professor of Clinical Medicine
University of California, San Francisco
San Francisco, California
Harvey Church—Patient Advocate
Columbia, Tennessee
Amy Gebhardt—Patient Advocate
Nashville, Tennessee
Steven Morrow—Patient Advocate
Franklin, Tennessee
Target Audience
This activity has been designed to meet the educational needs of community hematologist-oncologists and other health care providers involved in the care of RRMM patients.
Learning Objectives
After completing this activity, participants should be better able to:
- Evaluate recent clinical advances in the use of bispecific antibody therapy in patients with RRMM and their implications for clinical practice
- Summarize the toxicity profiles of bispecific antibodies used in the treatment of RRMM, particularly with respect to CRS, neurotoxicity, and infections
- Employ the recommended strategies to monitor for treatment complications and manage AEs associated with bispecific antibody therapy
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. RedMedEd, the Multiple Myeloma Research Foundation, Johnson & Johnson, and Pfizer do not recommend the use of any agent outside the labeled indications.
Disclaimer
The information presented in this activity is for medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of RedMedEd, the Multiple Myeloma Research Foundation, Johnson & Johnson, or Pfizer. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Contact Information
For questions related to this activity, please contact RedMedEd at 610.251.6841 or education@redmeded.com.
Privacy Policy
This content is managed by RedMedEd, and RedMedEd’s printed privacy policy applies to this site. The information you provide on this site may be used to contact you about other relevant educational activities. RedMedEd will not knowingly share any personally identifiable information. For more information, contact education@redmeded.com.
Copyright
© 2024. This program is held as copyrighted by the Multiple Myeloma Research Foundation and RedMedEd. Through this notice, the Multiple Myeloma Research Foundation and RedMedEd grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.